CUT Protocol
Retatrutide R40 Maintenance Pen
Retatrutide maintenance — one pen, one month, your dose.
Technical Specifications
Key Attributes
- One-month supply at your confirmed individual maintenance dose
- Seamless transition from R25 or R50 onboarding — identical click precision
- Avoids over-supplying volume beyond what your monthly protocol requires
- Available on an ongoing basis through private access in Bangkok and Thailand
- Quality-controlled European-sourced Retatrutide — consistent batch to batch
Biohackr.Labs provides product education, protocol guidance, and private client support. Information on this website is not medical advice and does not replace consultation with a licensed healthcare professional.
What's Included
Premium hard case.
Everything included.
Every Biohackr.Labs pen ships in our premium white hard case — holographic logo, foam-fitted interior. Inside: the precision pen, ten individually sealed 31G 8mm micro needles, and all documentation needed to begin your protocol correctly.
Precision pen
Pre-filled, batch quality-controlled pen system ready at your confirmed starting dose.
10× 31G micro needles
31G 8mm individually sealed sterile micro needles. Ten included as standard with every pen.
Protocol card
Starting dose, titration schedule, session guidance, and what to expect — specific to your protocol.
Batch QC documentation
Batch reference, preparation date, and compound specification. Not boilerplate — specific to your order.
Storage & handling guide
Temperature requirements, travel guidance, and handling notes with Bangkok climate context.
WhatsApp support access
Direct channel access throughout your protocol for questions, dose adjustments, and guidance.
Cold-Chain Delivery
Professionally packed
for Bangkok logistics.
Every Biohackr.Labs order is individually sealed, temperature-controlled, and dispatched in protective cold-chain packaging engineered to maintain product integrity from preparation to your door.
2–8°C maintained
Insulated inner liner and cold-pack keep the product in range throughout Bangkok transit.
Discreet outer packaging
Plain kraft outer box — no branding, no product name, no external indication of contents.
Tamper-evident sealing
Every product is individually sealed before dispatch. Integrity is visible at handover.
Step 01
Protocol Overview
“Retatrutide maintenance — one pen, one month, your dose.”
The R40 Maintenance Pen is designed for clients who have completed a structured Retatrutide onboarding protocol and confirmed their effective dose. Delivering 40 mg across 160 precision clicks, the R40 provides exactly one month of maintenance-phase support at the dose that works for you — without the larger volume of an onboarding pen. The rational next step after completing the R25 or R50.
Step 02
Mechanism of Action
In the maintenance phase of a Retatrutide protocol, the goal shifts from dose escalation to sustained metabolic equilibrium. The R40 delivers your confirmed effective dose consistently across a monthly cycle, supporting continued appetite regulation, metabolic rate maintenance, and body composition stability. The 0.25 mg per click precision remains identical to the onboarding pens, ensuring no dosing disruption at transition.
Suggested Use
One weekly subcutaneous administration at your confirmed maintenance dose. Dose confirmed through prior protocol and private onboarding review.
Who This Protocol Is For
For established Retatrutide users in Bangkok and Thailand who have completed onboarding and confirmed their effective dose. Not a starting protocol — requires prior onboarding and dose confirmation.
Storage — Bangkok & Thailand
Refrigerate between 2–8°C. Consistent storage is especially important for ongoing monthly protocols — establish a permanent refrigerated storage location before beginning maintenance phase.
Potential Side Effects
- GI effects — typically diminish once maintenance dose is established through onboarding; report any persistence through private access
- Injection site reactions — transient redness or discomfort at administration site
- Dysesthesia (tingling or altered skin sensation) — reported at higher doses; relevant if dose increases from confirmed maintenance level
- Cardiac effects under active investigation in ongoing Phase 3 trials — prior medical suitability review required
Private Access Required
All Biohackr.Labs protocols are guided through private client onboarding. Dosing and administration are confirmed per client before access is granted.
Enquire on WhatsAppThe Compound
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic once-weekly peptide developed by Eli Lilly — the first triple hormone receptor agonist to enter Phase 3 clinical trials. Where semaglutide activates one receptor and tirzepatide activates two, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. This triple mechanism produces compounding effects on appetite, fat metabolism, and energy expenditure that neither dual nor single agonists can replicate.
By targeting three complementary metabolic pathways at once, retatrutide addresses the biology of excess weight from multiple angles simultaneously. The result is weight loss outcomes that exceed what single or dual agonist compounds can achieve — including outcomes comparable to bariatric surgery in a subset of patients.
Semaglutide
Ozempic / Wegovy
Mechanism
GLP-1 only
Peak weight loss
~13.9%
Tirzepatide
Mounjaro / Zepbound
Mechanism
GLP-1 + GIP
Peak weight loss
~17.8–20.9%
Retatrutide
Pending (LY3437943)
Mechanism
GLP-1 + GIP + Glucagon
Peak weight loss
~25–30.3%
Cross-trial comparisons have inherent limitations. A head-to-head trial would be required for definitive conclusions.
Triple Mechanism
What Each Agonist Does
GLP-1
Glucagon-Like Peptide-1
Role
Appetite and insulin regulation
Slows gastric emptying to reduce caloric intake, suppresses appetite signals in the hypothalamus, and stimulates glucose-dependent insulin secretion. GLP-1 agonism is the foundation of semaglutide and tirzepatide — and the primary mechanism of all incretin-based compounds.
Key Effect
Appetite reduction + insulin sensitivity
Also in: Semaglutide, Tirzepatide
GIP
Glucose-dependent Insulinotropic Polypeptide
Role
Nutrient partitioning and fat cell metabolism
Enhances insulin sensitivity in peripheral tissues, modulates how the body partitions incoming calories between storage and use, and appears to amplify the appetite-suppressing effects of GLP-1 agonism. GIP is the second receptor targeted by tirzepatide — and a key contributor to its weight loss advantage over semaglutide.
Key Effect
Enhanced insulin sensitivity + fat cell regulation
Also in: Tirzepatide
Glucagon
Glucagon Receptor
Role
Energy expenditure and direct liver fat clearance
The critical differentiator. Glucagon receptor activation directly stimulates the liver to burn stored fat (fatty acid oxidation) and suppresses new fat synthesis (de novo lipogenesis). It also increases basal metabolic rate and thermogenesis — meaning the body burns more calories at rest. No approved obesity medication targets this receptor. It is the mechanism responsible for retatrutide's unprecedented liver fat reduction data.
Key Effect
Increased energy expenditure + hepatic fat clearance
Also in: Unique to Retatrutide among approved/late-stage compounds
Beyond Weight Loss
Emerging Benefits From Clinical Data
Clinical trial data surfacing across the TRIUMPH program suggests retatrutide may offer systemic benefits beyond weight management — driven by the glucagon receptor component that neither semaglutide nor tirzepatide possess.
Metabolic Liver Disease (MASLD/MASH)
The glucagon receptor component drives direct hepatic fat oxidation — the liver burns its stored triglycerides. Phase 2a data (Nature Medicine, 2024) showed 86% liver fat reduction and 90% complete resolution, unprecedented for any pharmacological agent. Phase 3 MASLD/MASH-specific trials are underway.
Knee Osteoarthritis
TRIUMPH-4 (Dec 2025) demonstrated substantial reduction in knee pain and improved physical function in patients with obesity and osteoarthritis — the first Phase 3 drug trial to show this combination of weight and pain outcomes simultaneously.
Systemic Inflammation
TRIUMPH-1 investigators noted "clear improvements in assessed cardiometabolic health measures" including inflammatory markers. The triple receptor mechanism appears to address metabolic inflammation through multiple pathways — weight-independent of the pure weight loss effect.
Insulin Resistance
Significant reductions in HOMA-IR (the standard measure of insulin resistance) have been observed across both Phase 2 and Phase 3 data, suggesting potential utility in pre-diabetic and early diabetic metabolic profiles beyond weight alone.
Sleep Apnoea
A dedicated TRIUMPH trial arm is evaluating retatrutide in adults with obesity and moderate-to-severe obstructive sleep apnoea. Results expected 2026. GLP-1 class compounds have shown sleep apnoea benefit proportional to weight loss; the triple mechanism may amplify this further.
Cardiovascular Outcomes
TRIUMPH-3 is studying retatrutide specifically in adults with established cardiovascular disease — one of the highest-risk obesity populations. The SELECT trial established semaglutide reduces major cardiovascular events by ~20%; whether triple agonism improves this further is the core question. Results expected 2026.
All emerging benefit data is from Phase 2 or Phase 3 clinical trial publications and official Eli Lilly announcements. Retatrutide is investigational. Benefits described are not confirmed clinical indications.
Live Research
TRIUMPH Trial Tracker
Last updated
June 2026
Eli Lilly TRIUMPH Phase 3 · 5 trials · 5,800+ participants
25.0% avg weight loss at 80 weeks (12 mg). 30.3% at 104 weeks. 45.3% lost >30% bodyweight.
Results expected Q2–Q3 2026.
Results expected 2026. Will evaluate MACE outcomes with triple agonism.
28.7% avg weight loss at 68 weeks (12 mg). Substantial knee pain reduction.
Phase 2a: 86% liver fat reduction. Phase 3 results expected 2026.
FDA submission anticipated 2026–2027 following full TRIUMPH program readouts. · All data from official Eli Lilly press releases and peer-reviewed publications. Retatrutide is investigational and not approved for clinical use.
Key Statistics
Phase 3 TRIUMPH Data Highlights
30.3%
Average weight loss at 104 weeks
12 mg dose, TRIUMPH-1 — comparable to bariatric surgery outcomes
Eli Lilly, May 2026
45.3%
Patients losing >30% body weight
12 mg dose — a threshold historically achievable only through surgery
TRIUMPH-1, May 2026
70.3 lbs
Average weight lost at 80 weeks
12 mg dose, TRIUMPH-1 — highest weight loss for any non-surgical intervention in Phase 3
Eli Lilly, May 2026
86%
Liver fat reduction at 48 weeks
12 mg dose, Phase 2a liver sub-study — unprecedented for any pharmacological compound
Nature Medicine, 2024
90%
Patients achieving complete liver fat resolution
<5% liver fat — effectively clearing hepatic steatosis in 9 of 10 participants
Nature Medicine, 2024
5,800+
Participants enrolled in TRIUMPH program
Across four global registrational trials — the largest retatrutide trial program to date
Eli Lilly, 2026
Same Collection
Related CUT Protocols
Private Access
Premium imported peptide pens in Bangkok.
Private protocol access · European-sourced · Quality-controlled · Thailand delivery
Enquire About Retatrutide R40 Maintenance Pen